Michael Engsig
Chief Executive Officer Nykode Therapeutics
Michael Engsig has more than 20 years of international experience within the pharmaceutical industry, from early-stage drug discovery to late-stage development and product launches in biotech and pharma across all major geographical areas, in both capital markets and publicly listed companies. His career history includes specialist and managerial roles at Takeda and Nycomed, with a successful track record in general management, R&D and commercial functions. Since 2019 Michael has been CEO at Nykode Therapeutics, Norway. Michael holds a civil engineering (MSc) degree in chemistry specializing in biotechnology from the Technical University of Denmark, and a Graduate Diploma in Business Administration (HD) in organization and leadership from the Copenhagen Business School (CBS).
Seminars
Reducing vein-to-vaccine timelines and achieving sustainable cost of goods requires more than operational optimization alone. This workshop will explore where speed and cost are truly won or lost across development, manufacturing, testing, and supply chain strategy, and what it takes to build commercially scalable personalized cancer vaccine programs.
Join this workshop to:
- Identify which platform-level design choices (formulation complexity, cold-chain dependency, antigen design/selection speed) set the real ceiling on vein-to-vaccine timelines, independent of downstream process optimization
- Explore how advances in antigen design and selection are compressing design-to batch-release timelines across different technology approaches
- Optimize analytical and assay strategies to enable rapid batch release while maintaining product quality, safety, and regulatory compliance
- Benchmark COGS drivers across personalized cancer vaccine technologies to identify where sustainable commercial economics are actually won or lost
